Toxicologic Pathology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Walsh, K. M.
Right arrow Articles by Rothwell, C. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Walsh, K. M.
Right arrow Articles by Rothwell, C. E.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Toxicologic Pathology, Vol. 27, No. 4, 395-401 (1999)
DOI: 10.1177/019262339902700402

Hepatic Effects in Beagle Dogs Administered Atorvastatin, a 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor, for 2 Years

Kathleen M. Walsh

Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan

Charles E. Rothwell

Parke-Davis Pharmaceutical Research, Division of Warner-Lambert Company, Ann Arbor, Michigan

The chronic toxicity of atorvastatin (AT), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, was evaluated in beagle dogs. Dogs were treated with 0, 10, 40, or 120 mg/kg of AT daily. Treatment lengths were 52 wk, 52 wk followed by 12 wk without drug, or 104 wk. Decreases in cholesterol levels were dose related and stable throughout the treatment period. Increases in alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase were transient and dose related in severity at ≥40 mg/kg. Two dogs administered 120 mg/kg of AT daily were sacrificed moribund during the first 9 wk of treatment. Hepatic lesions were reversible with or without continued treatment and dose related in severity and distribution. Hepatic microgranulomas and hepatocellular degeneration were seen at the 120-mg/kg dose in dogs sacrificed before 53 wk. Before 53 wk, hepatocellular lipofuscin deposits were increased in dogs given ≥40 mg/kg of AT daily but were similar to controls after 12 wk without drug and after 104 wk of continuous treatment. Bile stasis occurred in dogs given ≥40 mg/kg of AT daily at all time points but was less severe after reversal and at week 104 compared with week 52.

Key Words: Lipid regulation • liver • cholesterol • microgranuloma • lipofuscin


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
J. S. MacDonald and M. M. Halleck
The Toxicology of HMG--CoA Reductase Inhibitors: Prediction of Human Risk
Toxicol Pathol, February 1, 2004; 32(2_suppl): 26 - 41.
[Abstract] [PDF]

Home page
 Toxicol SciHome page
L. A. Dostal, P. Juneau, and C. E. Rothwell
Repeated Analysis of Semen Parameters in Beagle Dogs during a 2-Year Study with the HMG-CoA Reductase Inhibitor, Atorvastatin
Toxicol. Sci., May 1, 2001; 61(1): 128 - 134.
[Abstract] [Full Text] [PDF]